Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.
Attend the travel industry’s leading events and learn from the top executives and creatives shaping travel’s future. The age of AI has introduced a complicated and exciting duality of ...